We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+8.23%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.74B
AUM Growth
-$74.6M
(-2%)
Cap. Flow
-$193M
Cap. Flow
% of AUM
-5.15%
Top 10 Holdings %
Top 10 Hldgs %
49.32%
Holding
151
New
26
Increased
20
Reduced
26
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRNX
Crinetics Pharmaceuticals
CRNX
|
+$76.8M |
| 2 |
ATNX
Athenex, Inc. Common Stock
ATNX
|
+$47.1M |
| 3 |
VRAY
ViewRay, Inc.
VRAY
|
+$35.6M |
| 4 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$21.3M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$65.3M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$64.5M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$57.5M |
| 4 |
Humana
HUM
|
+$36.8M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$35.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.11% |
| 2 | Miscellaneous | 5.71% |
| 3 | Consumer Staples | 0.92% |
| 4 | Financials | 0.17% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Humana
HUM
$47.6B
| $11.8M | 0.32% |
35,000
-113,218
| -76% | -$36.8M |
|
52
Wave Life Sciences
WVE
$879M
| $11.7M | 0.31% |
234,019
-48,779
| -17% | -$2.2M |
|
|
ABMD
53
DELISTED
Abiomed Inc
ABMD
| $10.7M | 0.29% |
23,800
-12,846
| -35% | -$5.06M |
|
|
MTEM
54
DELISTED
Molecular Templates, Inc.
MTEM
| $10.6M | 0.28% |
131,609
+83,333
| +173% | +$6.39M |
|
|
AMRN
55
Amarin Corp
AMRN
$294M
| $9.93M | 0.27% |
+30,510
| New | +$2.3M |
|
56
TherapeuticsMD
TXMD
$25M
| $9.84M | 0.26% |
+30,000
| New | +$9.19M |
|
|
MRNS
57
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $9.08M | 0.24% |
226,933
| – | – |
|
|
ADMS
58
DELISTED
Adamas Pharmaceuticals
ADMS
| $8.45M | 0.23% |
422,015
-662,144
| -61% | -$15.5M |
|
|
TSRO
59
DELISTED
TESARO, Inc.
TSRO
| $7.8M | 0.21% |
200,000
+100,000
| +100% | +$3.53M |
|
60
CareDx
CDNA
$2.72B
| $7.52M | 0.2% |
260,676
-207,000
| -44% | -$3.87M |
|
61
Arrowhead Research
ARWR
$9.98B
| $7.01M | 0.19% |
365,445
| – | – |
|
|
EIDX
62
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $6.86M | 0.18% |
686,922
| – | – |
|
|
PTE
63
DELISTED
PolarityTE, Inc. Common Stock
PTE
| $6.43M | 0.17% |
+13,473
| New | +$7.77M |
|
64
eHealth
EHTH
$28.5M
| $6.39M | 0.17% |
+226,220
| New | +$6.01M |
|
|
OMED
65
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $5.56M | 0.15% |
2,620,897
| – | – |
|
|
UROV
66
DELISTED
Urovant Sciences Ltd.
UROV
| $5.55M | 0.15% |
+462,659
| New | +$5.47M |
|
|
SRRA
67
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $5.44M | 0.15% |
80,000
-32,500
| -29% | -$2.95M |
|
|
ABEOW
68
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
| $5.14M | 0.14% |
659,636
-600,000
| -48% | -$5.57M |
|
|
TBIO
69
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $5M | 0.13% |
500,000
| – | – |
|
|
CLVS
70
DELISTED
Clovis Oncology, Inc.
CLVS
| $4.41M | 0.12% |
+150,000
| New | +$5.81M |
|
71
Neuronetics
STIM
$213M
| $4.34M | 0.12% |
135,500
+10,000
| +8% | +$304K |
|
72
PUT
Geron
GERN
$842M
| $3.68M | 0.1% |
+1,950,000
| New | +$8.5M |
|
|
ACHN
73
DELISTED
Achillion Pharmaceuticals
ACHN
| $3.68M | 0.1% |
1,000,000
| – | – |
|
74
Xeris Biopharma Holdings
XERS
$1.37B
| $3.53M | 0.09% |
200,627
-249,373
| -55% | -$5.41M |
|
75
Evolent Health
EVH
$423M
| $3.12M | 0.08% |
110,000
+40,000
| +57% | +$954K |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q3 2018 Portfolio in Review
As of Q3 2018, Perceptive Advisors held 151 positions worth $3.74B, down 2% from $3.81B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Perceptive Advisors withdrew a net $193M in Q3 2018, closing 34 positions and reducing 26 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $57.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Perceptive Advisors opened a new position in Crinetics Pharmaceuticals worth $74.1M.
- Perceptive Advisors's largest Q3 2018 buy was Crinetics Pharmaceuticals: 2,587,953 shares worth $74.1M.
- Perceptive Advisors added most to Athenex, Inc. Common Stock in Q3 2018, an estimated $47.1M increase.
- Perceptive Advisors's biggest Q3 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $65.3M.
- Perceptive Advisors fully exited Alexion Pharmaceuticals in Q3 2018, selling an estimated $57.5M.
- Perceptive Advisors's ten largest holdings make up 49% of its $3.74B portfolio in Q3 2018.
- Perceptive Advisors opened 26 new positions and closed 34 in Q3 2018.
- Perceptive Advisors's portfolio value fell 2% quarter-over-quarter to $3.74B.
Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.